Aragen Bioscience and Innovent Biologics Announce Collaboration for Biotherapeutic Product Development
(Morgan Hill, CA; April 3, 2013) — Aragen Bioscience, Inc. and Innovent Biologics, Inc. have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Under the terms of the agreement, Aragen Bioscience is developing robust CHO cell lines and assessing critical product quality attributes for various antibodies and protein therapeutics.
"Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization. We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products," said Michael Yu, CEO of Innovent.
A contract research organization that offers a complete range of high-quality services, Aragen Bioscience focuses on customer service and technical leadership to enable clients to cost-effectively accelerate their research efforts. Aragen Bioscience offers cell line development, protein expression and purification, molecular biology, cell biology immunology and diverse in vivo services to the biotech and pharmaceutical
"Innovent is a great partner for the clinical development of biologic products expressed by the cell lines we have generated. We look forward to the expansion of the collaboration," said Oren Beske, Ph.D., vice president of Aragen Bioscience.
About Aragen Bioscience, Inc.
Aragen Bioscience, Inc. is a privately held contract research organization with offices and laboratories in
the San Francisco Bay Area. Aragen Bioscience offers a diverse set of services for the discovery,
characterization, activity assessment and early development of biologics and small molecules of interest.
For additional information, please visit www.aragenbio.com.
About Innovent Biologics, Inc.
Innovent Biologics, Inc., a privately held biopharmaceutical company funded by Fidelity and Lilly in the
U.S., is dedicated to the development and manufacturing of monoclonal antibodies and other
biopharmaceuticals to be marketed in China and elsewhere around the world. Innovent has four products
in development with disposable bioreactor production lines in a GMP plant. For additional information
about the company, please visit www.innoventbio.com.